Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2013
  • Online publication date: March 2013

Section 3 - Impact of cancers and treatment on male fertility

References

1. Galarneau GJ, Nagler HM. Cost-effective infertility therapies in the ‘90s: to treat or to cure? Contemp Urol 1999; 11: 32–45.
2. Gandini L, Sgro P, Lombardo F, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod 2006; 21: 2882–9.
3. Lass A, Akabosu F, Brinsden P. Sperm banking and assisted reproduction treatment for couples following cancer treatment of the male partner. Hum Reprod Update 2001; 7: 370–7.
4. Stahl O, Eberhard J, Jepson K, et al. The impact of testicular carcinoma and its treatment on sperm DNA integrity. Cancer 2004; 100: 1137–44.
5. Siegel R, Ward E, Brawley O, Jemal A. Cancer Statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212–36.
6. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917–31.
7. Shalet SM, Tsatsoulis A, Whitehead E, Read G. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol 1989; 120: 161–5.
8. Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant 2002; 30: 447–541.
9. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001; 7: 394–403.
10. Martin RH, Hildebrand K, Yamamoto J. An increased frequency of human sperm chromosomal abnormalities after radiotherapy. Mutat Res 1986; 174: 219–25.
11. Brent RL. Utilization of developmental basic science principles in the evaluation of reproductive risks form pre and postconception environmental radiation exposures. Teratology 1999; 59: 182–204.
12. Shah FJ, Tanaka M, Nielsen JE, et al. Gene expression profiles of mouse spermatogenesis during recovery from irradiation. Reprod Biol Endocrinol 2009; 7: 130.
13. Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974; 59: 665–78.
14. van Alphen MM, van de Kant HJ, de Rooij DG. Depletion of the spermatogonia from the seminiferous epithelium of the rhesus monkey after X irradiation. Radiation Research 1988; 113: 473–86.
15. van Alphen MM, van de Kant HJ, de Rooij DG. Repopulation of the seminiferous epithelium of the rhesus monkey after X irradiation. Radiation Research 1988; 113: 487–500.
16. van Alphen MM, van de Kant HJ, de Rooij DG. Follicle stimulating hormone stimulates spermatogenesis in the adult monkey. Endocrinology 1988; 123: 1449–55.
17. van Alphen MM, van de Kant HJ, Davids JA, et al. Dose-response studies on the spermatogonial stem cells of the rhesus monkey (Macaca mulatta) after X irradiation. Radiation Research 1989; 119: 443–51.
18. van Alphen MM, van de Kant HJ, de Rooij DG. Protection from radiation-induced damage of spermatogenesis in the rhesus monkey (Macaca mulatta) by follicle-stimulating hormone. Cancer Research 1989; 49: 533–6.
19. Clifton DK, Bremner WJ. The effect of testicular X-irradiation on spermatogenesis in man. A comparison with the mouse. J Andrology 1983; 4: 387–92.
20. Huhtaniemi I, Nikula H, Parvinen M, Rannikko S. Pituitary–testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis. J Androl 1987; 8: 363–73.
21. Meistrich ML. Hormonal stimulation of the recovery of spermatogenesis following chemo or radiotherapy. Acta Pathol Microbiol Immunol 1998; 106: 37–46.
22. Meistrich ML, Wilson G, Huhtaniemi I. Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. Cancer Res 1999; 59: 3557–60.
23. Meistrich ML, Wilson G, Kangasniemi M, Huhtaniemi I. Mechanism of protection of rat spermatogenesis by hormonal pretreatment: stimulation of spermatogonial differentiation after irradiation. J Androl 2000; 21: 464–9.
24. Shuttlesworth GA, de Rooij DG, Huhtaniemi I, et al. Enhancement of A spermatogonial proliferation and differentiation in irradiated rats by gonadotropin-releasing hormone antagonist administration. Endocrinology 2000; 141: 37–49.
25. Morse HC, Horike N, Rowley MJ, Heller CG. Testosterone concentrations in testes of normal men: effects of testosterone propionate administration. J Clin Endocrinol Metabol 1973; 37: 882–6.
26. Weinbauer GF, Nieschlag E. The role of testosterone in spermatogenesis. In Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution, 2nd edn. Heidelberg: Springer, 1998; pp. 143–68.
27. Weinbauer GF, Gromoll J, Simoni S, Nieschlag E. Physiology of testicular function. In Nieschlag E, Behre HM, eds. Andrology: Male Reproductive Health and Dysfunction, 2nd edn. Heidelberg: Springer, 2000; pp. 23–61.
28. McLachlan RI, O’Donnell L, Stanton PG, et al. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metabol 2002; 87: 546–56.
29. Kamischke A, Kuhlmann M, Weinbauer GF, et al. Gonadal protection from radiation by GnRH antagonist or recombinant human FSH: a controlled trial in a male nonhuman primate (Macaca fascicularis). J Endocrinol 2003; 179; 183–94.
30. Nielsen J, Hansen M, Jørgensen M, et al. Germ cell differentiation-dependent and stage-specific expression of LANCL1 in rodent testis. Eur J Histochem 2003; 47: 215–22.
31. Almstrup K, Nielsen J, Hansen M, et al. Analysis of cell-type-specific gene expression during mouse spermatogenesis. Biol Reprod 2003; 70: 1751–61.
32. Fattibene P, Mazzei F, Nuccetelli C, Risica S. Prenatal exposure to ionizing radiation: sources, effects and regulatory aspects. Acta Paediatr 1999; 88: 693–702.
33. Lord BI. Transgenerational susceptibility to leukaemia induction resulting from preconception paternal irradiation. Int J Radiat Biol 1999; 75: 801–10.
34. Meistrich ML. Critical components of testicular function and sensitivity to disruption. Biol Reprod 1986; 34: 17–28.
35. Brinkworth MH. Paternal transmission of genetic damage: findings in animals and humans. Int J Androl 2000; 23: 123–35.
36. Russell WL, Bangham JW, Russell LB. Differential response of mouse male germ-cell stages to radiation-induced specific-locus and dominant mutations. Genetics 1998; 148: 1567–78.
37. Stahl O, Eberhard J, Jepson K, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: the impact of testicular carcinoma and its treatment on sperm DNA integrity. Cancer 2004; 100: 1137–44.
38. Cordelli E, Fresegna AM, Leter G, et al. Evaluation of DNA damage in different stages of mouse spermatogenesis after testicular X irradiation. Radiat Res 2003; 160: 443–51.
39. Dubrova YE, Nesterov VN, Krouchinsky NG, et al. Human mini-satellite mutation rate after the Chernobyl accident. Nature 1996; 380: 683–6.
40. Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet 1998; 62: 45–52.
41. Kamiguchi Y, Tateno H. Radiation- and chemical-induced structural chromosome aberrations in human spermatozoa. Mutat Res 2002; 504: 183–91.
42. Stahl O, Boyd HA, Giwercman A, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst 2011; 103: 398–406.
43. Ishiguro H, Yasuda Y, Tomita Y, et al. Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence. Bone Marrow Transplant 2007; 39: 483–90.

References

1. Schrader M, Müller M, Straub B, Miller K. The impact of chemotherapy on male fertility: a survey of the biologic basis and clinical aspects. Reprod Toxicol 2001; 15: 611–17.
2. Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002; 20: 1880–9.
3. De Rooij D, Russell LD. All you wanted to know about spermatogonia but were afraid to ask. J Androl 2000: 21; 776–98.
4. Meistrich ML, Wilson G, Huhtaniemi I. Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. Cancer Res 1999; 59: 3557–60.
5. Bordallo MA, Guimaraes MM, Pessoa CH, et al. Decreased serum inhibin B/FSH ratio as a marker of Sertoli cell function in male survivors after chemotherapy in childhood and adolescence. J Pediatr Endocr Metab 2004; 17: 879–87.
6. Bahadur G, Ling KL, Hart R, et al. Semen quality and cryopreservation in adolescent cancer patients. Hum Reprod 2002; 17: 3157–61.
7. Dohle GR. Male infertility in cancer patients: review of the literature. Int J Urol 2010; 17: 327–31.
8. Foster RS, Rubin LR, McNulty A, Bihrle R, Donohue JP. Detection of antisperm-antibodies in patients with primary testicular cancer. Int J Androl 1991; 14: 179–85.
9. Ho GT, Gardner H, DeWolf WC, Loughlin KR, Morgentaler A. Influence of testicular carcinoma on ipsilateral spermatogenesis. J Urol 1992; 148: 821–5.
10. Lass A, Akagbosu F, Abusheikha N, et al. A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility centre: lessons from 8 years’ experience. Hum Reprod 1998; 13: 3256–61.
11. Petersen PM, Skakkebaek NE, Giwercman A. Gonadal function in men with testicular cancer: biological and clinical aspects. Acta Path Micro IM C 1998; 106: 24–36.
12. Petersen PM, Giwercman A, Hansen SW, et al. Impaired testicular function in patients with carcinoma in situ of the testis. J Clin Oncol 1999; 17: 173–9.
13. Jacobsen KD, Fosså SD, Bjøro TP, et al. Gonadal function and fertility in patients with bilateral testicular germ cell malignancy. Eur Urol 2002; 42: 229–38.
14. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals Oncology 2008; 19: 1795–801.
15. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 2010; 28: 168–79.
16. Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004; 100: 732–7.
17. Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30: 447–51.
18. Puscheck E, Philip PA, Jeyendran RS. Male fertility preservation and cancer treatment. Cancer Treat Rev 2004; 30: 173–80.
19. Thomson AB, Campbell AJ, Irvine DC, et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet 2002; 360: 361–7.
20. Shetty G, Meistrich ML. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. J Natl Cancer Inst Monogr 2005; 34: 36–9.
21. Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 1997; 68: 1–5.
22. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005; 34: 12–17.
23. Schrader M, Heicappell R, Müller M, Straub B, Miller K. Impact of chemotherapy on male fertility. Onkologie 2001; 24: 326–30.
24. Maymon BB, Yogev L, Marks A, et al. Sertoli cell inactivation by cytotoxic damage to the human testis after cancer chemotherapy. Fertil Steril 2004; 81: 1391–4.
25. Meistrich ML, Wilson G, Mathur K, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol 1997; 15: 3488–95.
26. van der Kaaij MA, Heutte N, Le Stang N, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007; 25: 2825–32.
27. van Beek RD, Smit M, van den Heuvel-Eibrink MM, et al. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood. Hum Reprod 2007; 22: 3215–22.
28. Spermon JR, Ramos L, Wetzels AM, et al. Sperm integrity pre- and post-chemotherapy in men with testicular germ cell cancer. Hum Reprod 2006; 21: 1781–6.
29. Stephenson WT, Poirier SM, Rubin L, Einhorn LH. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 1995; 13: 2278–80.
30. Ishikawa T, Kamidono S, Fujisawa M. Fertility after high-dose chemotherapy for testicular cancer. Urology 2004; 63: 137–40.
31. Wyrobek AJ, Schmid TE, Marchetti F. Relative susceptibilities of male germ cells to genetic defects induced by cancer chemotherapies. J Natl Cancer Inst Monogr 2005; 34: 31–5.
32. Robbins WA, Meistrich ML, Moore D, et al. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet 1997; 16: 74–8.
33. Thomas C, Cans C, Pelletier R, et al. No long-term increase in sperm aneuploidy rates after anticancer therapy: sperm fluorescence in situ hybridization analysis in 26 patients treated for testicular cancer or lymphoma. Clin Cancer Res 2004; 10: 6535–43.
34. Tempest HG, Ko E, Chan P, et al. Sperm aneuploidy frequencies analyzed before and after chemotherapy in testicular cancer and Hodgkin's lymphoma patients. Hum Reprod 2008; 23: 251–8.
35. O’Flaherty C, Hales BF, Chan P, Robaire B. Impact of chemotherapeutics on advanced testicular cancer or Hodgkin's lymphoma on sperm deoxyribonucleic acid. Fertil Steril 2010; 94: 1374–9.
36. Pentheroudakis G, Orecchia R, Hoekstra HJ, Pavlidis N; ESMO Guidelines Working Group. Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2010; 21 (Suppl 5): v266–73.

References

1. World Fertility Patterns 2009. United Nations Department of Economic and Social Affairs Population Division, 2010. www.un.org/esa/population/publications/worldfertility2009/worldfertility2009.htm (accessed January 2012).
2. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917–31.
3. Chapman RM, Sutcliffe SB, Rees LH, Edwards CR, Malpas JS. Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet 1979; 1: 285–9.
4. Meistrich ML. Male gonadal toxicity. Pediatr Blood Cancer 2009; 53: 261–6.
5. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med 2009; 360: 902–11.
6. Petersen PM, Skakkebaek NE, Vistisen K, Rorth M, Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999; 17: 941–7.
7. Hart R. Preservation of fertility in adults and children diagnosed with cancer. BMJ 2008; 337: a2045.
8. Meistrich ML, Byrne J. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer treated with potentially mutagenic therapies. Am J Hum Genet 2002; 70: 1069–71.
9. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol 1999; 33: 29–33.
10. Dodds L, Marrett LD, Tomkins DJ, Green B, Sherman G. Case-control study of congenital anomalies in children of cancer patients. BMJ 1993; 307: 164–8.
11. Brydoy M, Fossa SD, Dahl O, Bjoro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 2007; 46: 480–9.
12. Shin D, Lo KC, Lipshultz LI. Treatment options for the infertile male with cancer. J Natl Cancer Inst Monogr 2005; 34: 48–50.
13. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 2010; 28: 168–79.
14. Calamera JC, Morgenfeld MC, Mancini RE, Vilar O. Biochemical changes of the human semen produced by chlorambucil, testosterone propionate and human chorionic gonadotropin administration. Andrologia 1979; 11: 43–50.
15. Buchanan JD, Fairley KF, Barrie JU. Return of spermatogenesis after stopping cyclophosphamide therapy. Lancet 1975; 2: 156–7.
16. Bokemeyer C, Schmoll HJ, van Rhee J, et al. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994; 68: 105–10.
17. Ypsilantis P, Papaioannou N, Psalla D, et al. Effects of subchronic ifosfamide-mesna treatment on testes and semen characteristics in the rabbit. Reprod Toxicol 2003; 17: 699–708.
18. Pectasides D, Pectasides E, Papaxoinis G, et al. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy. J Androl 2009; 30: 280–6.
19. Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function? Pediatr Blood Cancer 2008; 50: 347–51.
20. Longhi A, Macchiagodena M, Vitali G, Bacci G. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol 2003; 25: 292–6.
21. Drasga RE, Einhorn LH, Williams SD, Patel DN, Stevens EE. Fertility after chemotherapy for testicular cancer. J Clin Oncol 1983; 1: 179–83.
22. Petersen PM, Hansen SW, Giwercman A, Rorth M, Skakkebaek NE. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994; 5: 355–8.
23. Brydoy M, Fossa SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97: 1580–8.
24. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001; 91: 1297–303.
25. Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15: 239–45.
26. Oxaliplatin package insert, version 5.0. Sanofi-Aventis Canada, Inc., 2010.
27. Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998; 19: 144–72.
28. Lee SJ. Preservation of fertility in patients with cancer. N Engl J Med 2009; 360: 2680.
29. Shamberger RC, Rosenberg SA, Seipp CA, Sherins RJ. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep 1981; 65: 739–46.
30. Chatzidarellis E, Makrilia N, Giza L, et al. Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis. Fertil Steril 2010; 94: 558–63.
31. Aubier F, Flamant F, Brauner R, et al. Male gonadal function after chemotherapy for solid tumors in childhood. J Clin Oncol 1989; 7: 304–9.
32. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010; 28: 4831–41.
33. Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991; 324: 93–103.
34. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007; 20: 305–11.
35. Fallat ME, Hutter J; Committee on Bioethics, Section on Hematology/Oncology, and Section on Surgery. Preservation of fertility in pediatric and adolescent patients with cancer. Pediatrics 2008; 121: e1461–9.
36. Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2677–85.
37. Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2010; 28: 332–9.
38. Green DM, Sklar CA, Boice JD, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2374–81.
39. Johnston RJ, Wallace WHB. Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. Pediatr Blood Cancer 2009; 5: 296–302.
40. Ridola V, Fawaz O, Aubier F, et al. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide and cyclophosphamide-based regimens. Eur J Cancer 2009; 45: 814–18.
41. Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101: 946–58.
42. Chemaitilly W, Sklar CA. Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 2010; 17: R141–59.
43. Yu AL, Gilman AL, Ozkaynak F, et al. Anti-GD2 antibody with GM-CSF, Interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324–34.
44. Laverdiere C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101: 1131–40.
45. Mansky P, Arai A, Stratton P, et al. Treatment late effects in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 2007; 48: 192–9.
46. Kayton ML, Wexler LH, Lewin SN, et al. Pediatric radical abdominal trachelectomy for anaplastic embryonal rhabdomyosarcoma of the uterine cervix: an alternative to radical hysterectomy. J Pediatr Surg 2009; 44: 862–7.
47. Greenberg DB, Goorin A, Gebhardt MC, et al. Quality of life in osteosarcoma survivors. Oncology 1994; 8: 19–25.
48. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1–12.
49. Horowitz M, Wexler L. Fertility in females after high cumulative dose alkylating agent therapy for pediatric sarcomas. American Society of Pediatric Hematology/Oncology, Ninth Annual Meeting, Chicago, IL, 1996.
50. Sudour H, Chastagner P, Claude L, et al. Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors. Int J Radiation Oncol Biol Phys 2010; 76: 867–73.
51. van den Berg H, Langeveld NE. Parental knowledge of fertility in male childhood cancer survivors. Psychooncology 2008; 17: 287–91.
52. Oktay K, Oktem O. Fertility preservation medicine: a new field in the care of young cancer survivors. Pediatr Blood Cancer 2009; 53: 267–73.
53. Weintraub M, Gross E, Kadari A, et al. Should ovarian cryopreservation be offered to girls with cancer. Pediatr Blood Cancer 2007; 48(1): 4–9.
54. Campo-Engelstein L. Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. J Clin Oncol 2010; 28: 1284–6.

References

1. Meistrich ML. Male gonadal toxicity. Pediatr Blood Cancer 2009; 53: 261–6.
2. Chapman RM, Sutcliffe SB, Malpas JS. Male gonadal dysfunction in Hodgkin's disease: a prospective study. JAMA 1981; 245: 1323–8.
3. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111: 71–6.
4. Sieniawski M, Reineke T, Josting A, et al., Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 2008; 19: 1795–801.
5. van der Kaaij MA, Heutte N, Le Stang N, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007; 25: 2825–32.
6. Pryzant RM, Meistrich ML, Wilson G, Brown B, McLaughlin P. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. J Clin Oncol 1993; 11: 239–47.
7. Bokemeyer C, Schmoll HJ, van Rhee J, et al. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994; 68: 105–10.
8. Kreuser ED, Hetzel WD, Heit W, et al. Reproductive and endocrine gonadal functions in adults following multidrug chemotherapy for acute lymphoblastic or undifferentiated leukemia. J Clin Oncol 1988; 6: 588–95.
9. Mariani S, Basciani S, Fabbri A, et al., Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril 2011; 95: 1120.e15–17.
10. Grigg AP, Stone J, Milner AD, et al. Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma 2010; 51: 641–9.

References

1. Hammond C, Abrams JR, Syrjala KL. Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls. J Clin Oncol 2007; 25: 3511–7.
2. Salooja N. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001; 358: 271–6.
3. Carter A. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant 2006; 37: 1023–9.
4. Loren A, Chow E, Jacobsohn D, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2011; 17: 157–66.
5. Chung K, Irani J, Knee G, et al. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obst Gynecol Reprod Biol 2004; 113: S7–S11.
6. van Casteren N, Boellaard W, Romijn J, Dohle GR. Gonadal dysfunction in male cancer patients before cytotoxic treatment. Int J Androl 2010; 33: 73–9.
7. Agarwal A, Allamaneni SSR. Disruption of spermatogenesis by the cancer disease process. J Natl Cancer Inst Monogr 2005; 34: 9–12.
8. Trottmann M, Becker AJ, Stadler T, et al. Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation. Eur Urol 2007; 52: 355–67.
9. Nakayama K, Milbourne A, Schover L, Champlin R, Ueno N. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nat Clin Pract Oncol 2008; 5: 78–89.
10. Viviani S. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21: 601–5.
11. Pryzant RM. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. J Clin Oncol 1993; 11: 239–47.
12. Leung W. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 2000; 18: 3273–9.
13. Lemez P, Urbnek V. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients. Neoplasma 2005; 52: 398–401.
14. Bahadur G, Ozturk O, Muneer A, et al. Semen quality before and after gonadotoxic treatment. Hum Reprod 2005; 20: 774–81.
15. Wallace WH. Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. Int J Androl 1991; 14: 312–9.
16. Waxman J. Gonadal function in men treated for acute leukaemia. Br Med J (Clin Res Ed) 1983; 287: 1093–4.
17. Howell S, Shalet S. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005; 34: 12–17.
18. Rovo A, Tichelli A, Passweg JR, et al. Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood 2006; 108: 1100–5.
19. Sanders J, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87: 3045–52.
20. Sanders JE. Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation 1983; 36: 252–5.
21. Jacob A. Recovery of spermatogenesis following bone marrow transplantation. Bone Marrow Transplant 1998; 22: 277–9.
22. Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant 2002; 30: 447–51.
23. Savani BN, Kozanas E, Shenoy A, et al. Recovery of spermatogenesis after total-body irradiation. Blood 2006; 108: 4292–4.
24. Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000; 26: 1089–95.
25. Jackson GH, Wood A, Taylor PR, et al. Early high dose chemotherapy intensification with autologous bone marrow transplantation in lymphoma associated with retention of fertility and normal pregnancies in females. Scotland and Newcastle Lymphoma Group, UK. Leuk Lymphoma 1997; 28: 127–32.
26. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373–85.
27. Chatterjee R, Mills W, Katz M, McGarrigle HH, Goldstone AH. Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma. Bone Marrow Transplant 1994; 13: 519–22.
28. Savani B, Kozanas E, Shenoy A, Barrett AJ. Recovery of spermatogenesis after total-body irradiation. Blood 2006; 108: 4292–3.
29. Kyriacou C, Kottaridis PD, Eliahoo J, et al. Germ cell damage and Leydig cell insufficiency in recipients of nonmyeloablative transplantation for haematological malignancies. Bone Marrow Transplant 2003; 31: 45–50.

References

1. Manecksha RP, Fitzpatrick JM. Epidemiology of testicular cancer. BJU Int 2009; 104: 1329–33.
2. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242–53.
3. Schover LR. Motivation for parenthood after cancer: a review. J Natl Cancer Inst Monogr 2005; 34: 2–5.
4. Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15: 239–45.
5. Lambert SM, Fisch H. Infertility and testis cancer. Urol Clin North Am 2007; 34: 269–77, xi.
6. Williams DH, Karpman E, Sander JC, et al. Pretreatment semen parameters in men with cancer. J Urol 2009; 181: 736–40.
7. Walsh TJ, Croughan MS, Schembri M, Chan JM, Turek PJ. Increased risk of testicular germ cell cancer among infertile men. Arch Intern Med 2009; 169: 351–6.
8. Wohlfahrt-Veje C, Main KM, Skakkebaek NE. Testicular dysgenesis syndrome: foetal origin of adult reproductive problems. Clin Endocrinol 2009; 71: 459–65.
9. Agarwal A, Tolentino MV, Sidhu RS, et al. Effect of cryopreservation on semen quality in patients with testicular cancer. Urology 1995; 46: 382–9.
10. Ho GT, Gardner H, Mostofi K, et al. The effect of testicular nongerm cell tumors on local spermatogenesis. Fertil Steril 1994; 62: 162–6.
11. Rueffer U, Breuer K, Josting A, et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol 2001; 12: 1307–11.
12. Hayashi T, Arai G, Hyochi N, et al. Suppression of spermatogenesis in ipsilateral and contralateral testicular tissues in patients with seminoma by human chorionic gonadotropin beta subunit. Urology 2001; 58: 251–7.
13. Hansen PV, Trykker H, Andersen J, Helkjaer PE. Germ cell function and hormonal status in patients with testicular cancer. Cancer 1989; 64: 956–61.
14. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917–31.
15. Clarke GN, Liu de Y, Baker HW. Recovery of human sperm motility and ability to interact with the human zona pellucida after more than 28 years of storage in liquid nitrogen. Fertil Steril 2006; 86: 721–2.
16. Kuczynski W, Dhont M, Grygoruk C, et al. The outcome of intracytoplasmic injection of fresh and cryopreserved ejaculated spermatozoa: a prospective randomized study. Hum Reprod 2001; 16: 2109–13.
17. Ohl DA, Denil J, Bennett CJ, et al. Electroejaculation following retroperitoneal lymphadenectomy. J Urol 1991; 145: 980–3.
18. Schrader M, Muller M, Sofikitis N, et al. “Onco-tese”: testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines? Urology 2003; 61: 421–5.
19. Magelssen H, Haugen TB, von During V, et al. Twenty years experience with semen cryopreservation in testicular cancer patients: who needs it? Eur Urol 2005; 48: 779–85.
20. Girasole CR, Cookson MS, Smith JA, Jr., et al. Sperm banking: use and outcomes in patients treated for testicular cancer. BJU Int 2007; 99: 33–6.
21. Achille MA, Rosberger Z, Robitaille R, et al. Facilitators and obstacles to sperm banking in young men receiving gonadotoxic chemotherapy for cancer: the perspective of survivors and health care professionals. Hum Reprod 2006; 21: 3206–16.
22. Sanger WG, Olson JH, Sherman JK. Semen cryobanking for men with cancer: criteria change. Fertil Steril 1992; 58: 1024–7.
23. Audrins P, Holden CA, McLachlan RI, Kovacs GT. Semen storage for special purposes at Monash IVF from 1977 to 1997. Fertil Steril 1999; 72: 179–81.
24. Blackhall FH, Atkinson AD, Maaya MB, et al. Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. Br J Cancer 2002; 87: 381–4.
25. Agarwal A, Ranganathan P, Kattal N, et al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril 2004; 81: 342–8.
26. Selk A, Belej-Rak T, Shapiro H, Greenblatt E. Use of an oncology sperm bank: a Canadian experience. Can Urol Assoc J 2009; 3: 219–22.
27. Toren PJ, Roberts M, Lecker I, et al. Small incidentally discovered testicular masses in infertile men–is active surveillance the new standard of care? J Urol 183: 1373–7.
28. Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 1999; 83: 815–22.
29. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005; 16: 863–8.
30. Ehrlich Y, Konichezky M, Yossepowitch O, Baniel J. Multifocality in testicular germ cell tumors. J Urol 2009; 181: 1114–19.
31. Heidenreich A, Weissbach L, Holtl W, et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001; 166: 2161–5.
32. Zuniga A, Lawrentschuk N, Jewett MA. Organ-sparing approaches for testicular masses. Nat Rev Urol 2010; 7(8): 454–64.
33. Berney DM. Staging and classification of testicular tumours: pitfalls from macroscopy to diagnosis. J Clin Pathol 2008; 61: 20–4.
34. Hopps CV, Goldstein M. Ultrasound guided needle localization and microsurgical exploration for incidental nonpalpable testicular tumors. J Urol 2002; 168: 1084–7.
35. Ragni G, Somigliana E, Restelli L, et al. Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients. Cancer 2003; 97: 1624–9.
36. Lass A, Akagbosu F, Abusheikha N, et al. A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility centre: lessons from 8 years’ experience. Hum Reprod 1998; 13: 3256–61.
37. Delouya G, Baazeem A, Boman JM, et al. Identification of spermatozoa in archived testicular cancer specimens: implications for bench side sperm retrieval at orchiectomy. Urology 75: 1436–40.
38. Carmignani L, Gadda F, Gazzano G, et al. Testicular sperm extraction in cancerous testicle in patients with azoospermia: a case report. Hum Reprod 2007; 22: 1068–72.
39. Baniel J, Sella A. Sperm extraction at orchiectomy for testis cancer. Fertil Steril 2001; 75: 260–2.
40. Binsaleh S, Sircar K, Chan PT. Feasibility of simultaneous testicular microdissection for sperm retrieval and ipsilateral testicular tumor resection in azoospermic men. J Androl 2004; 25: 867–71.
41. Choi BB, Goldstein M, Moomjy M, et al. Births using sperm retrieved via immediate microdissection of a solitary testis with cancer. Fertil Steril 2005; 84: 1508.
42. Carmignani L, Gadda F, Paffoni A, et al. Azoospermia and severe oligospermia in testicular cancer. Arch Ital Urol Androl 2009; 81: 21–3.
43. Carroll PR, Morse MJ, Whitmore WF, Jr., et al. Fertility status of patients with clinical stage I testis tumors on a surveillance protocol. J Urol 1987; 138: 70–2.
44. Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974; 59: 665–78.
45. Centola GM, Keller JW, Henzler M, Rubin P. Effect of low-dose testicular irradiation on sperm count and fertility in patients with testicular seminoma. J Androl 1994; 15: 608–13.
46. Fossa SD, Abyholm T, Normann N, Jetne V. Post-treatment fertility in patients with testicular cancer. III. Influence of radiotherapy in seminoma patients. Br J Urol 1986; 58: 315–19.
47. Nalesnik JG, Sabanegh ES, Jr., Eng TY, Buchholz TA. Fertility in men after treatment for stage 1 and 2A seminoma. Am J Clin Oncol 2004; 27: 584–8.
48. Pilarchopoulou K, Pectasides D. Late complications of chemotherapy in testicular cancer. Cancer Treat Rev 2010; 36: 262–7.
49. Stephenson WT, Poirier SM, Rubin L, Einhorn LH. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 1995; 13: 2278–80.
50. Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005; 93: 200–7.
51. Burrello N, Vicari E, La Vignera S, et al. Effects of anti-neoplastic treatment on sperm aneuploidy rate in patients with testicular tumor: a longitudinal study. J Endocrinol Invest 2011; 34: e121–5.
52. Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65: 832–6.
53. Kreuser ED, Hetzel WD, Hautmann R, Pfeiffer EF. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res 1990; 22: 494–8.
54. Kaufman MR, Chang SS. Short- and long-term complications of therapy for testicular cancer. Urol Clin North Am 2007; 34: 259–68, xi.
55. Sheinfeld J, Bartsch G, Bosl GJ. Surgery of testicular tumors. In Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell–Walsh Urology, 9th edn. Philadelphia, PA: Saunders, 2007.
56. Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol 1982; 127: 685–8.
57. Beck SD, Bey AL, Bihrle R, Foster RS. Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection. J Urol 2010; 184: 2078–80.
58. Chan PT, Palermo GD, Veeck LL, Rosenwaks Z, Schlegel PN. Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer 2001; 92: 1632–7.
59. Meseguer M, Garrido N, Remohi J, et al. Testicular sperm extraction (TESE) and ICSI in patients with permanent azoospermia after chemotherapy. Hum Reprod 2003; 18: 1281–5.
60. Damani MN, Master V, Meng MV, et al. Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol 2002; 20: 930–6.
61. Shin D, Lo KC, Lipshultz LI. Treatment options for the infertile male with cancer. J Natl Cancer Inst Monogr 2005; 34: 48–50.

References

1.Central Brain Tumor Registry of the United States statistical report: primary brain and central nervous system tumors diagnosed in the United States 2004–2006. CBTRUS, 2010. www.cbtrus.org (accessed January 2012).
2. DeAngelis LM, Gutin PH, Leibel SA, et al. Intracranial Tumors: Diagnosis and Treatment. London: Martin Duntz, 2002.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–96.
4. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917–31.
5. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010; 28: 4831–41.
6. Talbot JA, Sheldrick R, Caswell H, et al. Sexual function in men with epilepsy: how important is testosterone? Neurology 2008; 70: 1346–52.
7. Herzog AG, Drislane FW, Schomer DL, et al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 2005; 65: 1016–20.
8. Bauer J, Blumenthal S, Reuber M, et al. Epilepsy syndrome, focus location, and treatment choice affect testicular function in men with epilepsy. Neurology 2004; 62: 243–6.
9. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886–93.
10. Rattya J, Turkka J, Pakarinen AJ, et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001; 56: 31–6.
11. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–51.
12. Giagulli VA, Vermeulen A. Leydig cell function in infertile men with idiopathic oligospermic infertility. J Clin Endocrinol Metab 1988; 66: 62–7.
13. Stoffel-Wagner B, Bauer J, Flugel D, et al. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia 1998; 39: 1164–73.
14. Isojarvi JI, Lofgren E, Juntunen KS, et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 2004; 62: 247–53.
15. French J. Use of levetiracetam in special populations. Epilepsia 2001; 42 (Suppl 4): 40–3.
16. Wingfield JC, Sapolsky RM. Reproduction and resistance to stress: when and how. J Neuroendocrinol 2003; 15: 711–24.
17. Samuels MH, Luther M, Henry P, et al. Effects of hydrocortisone on pulsatile pituitary glycoprotein secretion. J Clin Endocrinol Metab 1994; 78: 211–15.
18. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366: 985–90.
19. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 2007; 9: 314–18.
20. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998; 27: 927–43.
21. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17: 2762–71.
22. Gibson NW, Hickman JA, Erickson LC. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl) imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one. Cancer Res 1984; 44: 1772–5.
23.Temodar prescribing information. Last updated November 2011. www.spfiles.com/pitemodar.pdf (accessed Januaray 2012).
24. Thompson MJ, Abdul-Rahman S, Baker TG, et al. Role of O6-alkylguanine-DNA alkyltransferase in the resistance of mouse spermatogenic cells to O6-alkylating agents. J Reprod Fertil 2000; 119: 339–46.
25. Palmieri C, Brock C, Newlands ES. Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma. J Neurooncol 2005; 73: 185.
26. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14: 1131–8.
27. Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs 2000; 9: 1383–96.
28. Littley MD, Shalet SM, Beardwell CG, et al. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 1989; 70: 145–60.
29. Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab 2005; 90: 6355–60.
30. Littley MD, Shalet SM, Beardwell CG, et al. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf) 1989; 31: 363–73.
31. Harrop JS, Davies TJ, Capra LG, et al. Hypothalamic-pituitary function following successful treatment of intracranial tumours. Clin Endocrinol (Oxf) 1976; 5: 313–21.
32. Constine LS, Woolf PD, Cann D, et al. Hypothalamic–pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328: 87–94.
33. Black KL, Yin D, Ong JM, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008; 1230: 290–302.
34. Burrow GN, Wortzman G, Rewcastle NB, et al. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981; 304: 156–8.
35. Dulipsingh L, Lassman MN. Images in clinical medicine. Pituitary apoplexy. N Engl J Med 2000; 342: 550.
36. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485–534.
37. Prescott RW, Johnston DG, Kendall-Taylor P, et al. Hyperprolactinaemia in men-response to bromocriptine therapy. Lancet 1982; 1: 245–8.
38. Buvat J, Lemaire A, Buvat-Herbaut M, et al. Hyperprolactinemia and sexual function in men. Horm Res 1985; 22: 196–203.
39. Young WF, Jr., Scheithauer BW, Kovacs KT, et al. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc 1996; 71: 649–56.
40. Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986; 81: 457–62.
41. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730–5.
42. Morris LF, Harrod MJ, Menter MA, et al. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993; 29: 913–16.
43. El-Beheiry A, El-Mansy E, Kamel N, et al. Methotrexate and fertility in men. Arch Androl 1979; 3: 177–9.
44. Shamberger RC, Rosenberg SA, Seipp CA, et al. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep 1981; 65: 739–46.
45. Arnon J, Meirow D, Lewis-Roness H, et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001; 7: 394–403.
46. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21: 601–5.
47. Lendon M, Hann IM, Palmer MK, et al. Testicular histology after combination chemotherapy in childhood for acute lymphoblastic leukaemia. Lancet 1978; 2: 439–41.
48. Lemez P, Urbanek V. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients. Neoplasma 2005; 52: 398–401.
49. Podnar S, Oblak C, Vodusek DB. Sexual function in men with cauda equina lesions: a clinical and electromyographic study. J Neurol Neurosurg Psychiatry 2002; 73: 715–20.
50. DeAngelis LM, Posner JB. Neurological Complication of Cancer, 2nd edn. New York, NY: Oxford University Press, 2009.

References

1. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19: 3163–72.
2. Campbell J, Wallace WH, Bhatti LA et al. Cancer in Scotland: trends in incidence, mortality, and survival 1975–1999. Edinburgh 2003: Information and Statistics Division. www.isdscotland.org/cancer_information (accessed January 2012).
3. Brougham MFH, Wallace WHB. Subfertility in children and young people treated for solid and haematological malignancies. Br J Haematol 2005; 131: 143–55.
4. Oosterhuis BE, Goodwin T, Kiernan M, et al. Concerns about infertility risks among pediatric oncology patients and their parents. Pediatr Blood Cancer 2008; 50: 85–9.
5. Meistrich ML, Finch M, da Cunha MF, et al. Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res 1982; 42: 122–31.
6. Bucci LR, Meistrich ML. Effects of busulfan on murine spermatogenesis: cytotoxicity, sterility, sperm abnormalities, and dominant lethal mutations. Mutat Res 1987; 176: 259–68.
7. Whitehead E, Shalet SM, Jones PH, et al. Gonadal function after combination chemotherapy for Hodgkin's disease in childhood. Arch Dis Child 1982; 57: 287–91.
8. Rey RA, Campo SM, Bedecarras P, et al. Is infancy a quiescent period of testicular development? Histological, morphometric, and functional study of the seminiferous tubules of the cebus monkey from birth to the end of puberty. J Clin Endocrinol Metab 1993; 76: 1325–31.
9. Chemes HE. Infancy is not a quiescent period of testicular development. Int J Androl 2001; 24: 2–7.
10. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol 1996; 27: 74–8.
11. Wallace WH, Shalet SM, Crowne EC, et al. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989; 17: 409–13.
12. Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol 1987; 113: 260–6.
13. Siimes MA, Rautonen J. Small testicles with impaired production of sperm in adult male survivors of childhood malignancies. Cancer 1990; 65: 1303–6.
14. Gerl A, Muhlbayer D, Hansmann G, et al. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001; 91: 1297–303.
15. Centola GM, Keller JW, Henzler M, Rubin P. Effect of low-dose testicular irradiation on sperm count and fertility in patients with testicular seminoma. J Androl 1994; 15: 608–13.
16. Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974; 59: 665–78.
17. Ash P. The influence of radiation on fertility in man. Br J Radiol 1980; 53: 271–8.
18. Shalet SM, Tsatsoulis A, Whitehead E, Read G. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol 1989; 120: 161–5.
19. Castillo LA, Craft AW, Kernahan J, et al. Gonadal function after 12-Gy testicular irradiation in childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1990; 18: 185–9.
20. Leiper AD, Stanhope R, Lau T, et al. The effect of total body irradiation and bone marrow transplantation during childhood and adolescence on growth and endocrine function. Br J Haematol 1987; 67: 419–26.
21. Littley MD, Shalet SM, Beardwell CG, et al. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf) 1989; 31: 363–73.
22. Schmiegelow M, Lassen S, Poulsen HS, et al. Gonadal status in male survivors following childhood brain tumors. J Clin Endocrinol Metab 2001; 86: 2446–52.
23. Rueffer U, Breuer K, Josting A, et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol 2001; 12: 1307–11.
24. Hallak J, Mahran A, Chae J, Agarwal A. The effects of cryopreservation on semen from men with sarcoma or carcinoma. J Assist Reprod Genet 2000; 17: 218–21.
25. Agarwal A, Shekarriz M, Sidhu RK, Thomas AJ. Value of clinical diagnosis in predicting the quality of cryopreserved sperm from cancer patients. J Urol 1996; 155: 934–8.
26. Brougham MFH, Levitt G on behalf of the Children's Cancer and Leukaemia Group, Late Effects Working Group. Subfertility Risk Consensus Document: Update 2010. www.cclg.org.uk (accessed January 2012).
27. Marmor D, Duyck F. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey. Andrologia 1995; 27: 99–106.
28. Anderson RA, Sharpe RM. Regulation of inhibin production in the human male and its clinical applications. Int J Androl 2000; 23: 136–44.
29. Wallace EM, Groome NP, Riley SC, et al. Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: a prospective longitudinal study. J Clin Endocrinol Metab 1997; 82: 3111–15.
30. Crofton PM, Thomson AB, Evans AEM, et al. Is inhibin B a potential marker of gonadotoxicity in prepubertal children treated for cancer? Clin Endocrinol (Oxf) 2003; 58: 296–301.
31. Anderson RA, Weddell A, Spoudeas HA, et al. Do doctors discuss fertility issues before they treat young patients with cancer? Hum Reprod 2008; 23: 2246–51.
32. Wallace WHB, Thomson AB. Preservation of fertility in children treated for cancer. Arch Dis Child 2003; 88: 493–6.
33. Postovsky S, Lightman A, Aminpour D, et al. Sperm cryopreservation in adolescents with newly diagnosed cancer. Med Pediatr Oncol 2003; 40: 355–9.
34. Clarke RN, Klock SC, Geoghegan A, Travassos DE. Relationship between psychological stress and semen quality among in-vitro fertilization patients. Hum Reprod 1999; 14: 753–8.
35. Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation. Proc Natl Acad Sci U S A 1994; 91: 11298–302.
36. Honaramooz A, Snedaker A, Boiani M, et al. Sperm from neonatal mammalian testes grafted in mice. Nature 2002; 418: 778–81.
37. Luetjens CM, Stukenborg JB, Nieschlag E, et al. Complete spermatogenesis in orthotopic but not in ectopic transplants of autologously grafted marmoset testicular tissue. Endocrinology 2008; 149: 1736–47.
38. Ginsberg JP, Carlson CA, Lin K, et al. An experimental protocol for fertility preservation in prepubertal boys recently diagnosed with cancer: a report on acceptability and safety. Hum Reprod 2010; 25: 37–41.
39. Goossens E, Frederickx V, Geens M, et al. Cryosurvival and spermatogenesis after allografting prepubertal mouse tissue: comparison of two cryopreservation protocols. Fertil Steril 2008; 89: 725–7.
40. Jahnukainen K, Hou M, Petersen C, et al. Intratesticular transplantation of testicular cells from leukemic rats causes transmission of leukemia. Cancer Res 2001; 61: 706–10.
41. Shinohara T, Avarbock MR, Brinster RL. Beta 1 and alpha 6-integrin are surface markers on mouse spermatogonial stem cells. Proc Natl Acad Sci U S A 1999; 96: 5504–9.
42. Gassei K, Ehmcke J, Dhir R, Schlatt S. Magnetic activated cell sorting allows isolation of spermatogonia from adult primate testes and reveals distinct GFRα1-positive subpopulations in men. J Med Primatol 2010; 39: 83–91.
43. Nagano M, Avarbock MR, Leonida EB, et al. Culture of mouse spermatogonial stem cells. Tissue Cell 1998; 30: 389–97.
44. Schlatt S, Rosiepen G, Weinbauer GF, et al. Germ cell transfer into rat, bovine, monkey and human testes. Hum Reprod 1999; 14: 144–50.
45. Tesarik J, Bahceci M, Ozcan C, et al. Restoration of fertility by in-vitro spermatogenesis. Lancet 1999; 353: 555–6.
46. Sato T, Katagiri K, Gohbara A, et al. In vitro production of functional sperm in cultured neonatal mouse testes. Nature 2011; 471: 504–7.
47. Ward JA, Robinson J, Furr BJ, et al. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Cancer Res 1990; 50: 568–74.
48. Meistrich ML, Kangasniemi M. Hormone treatment after irradiation stimulates recovery of rat spermatogenesis from surviving spermatogonia. J Androl 1997; 18: 80–7.
49. Kangasniemi M, Huhtaniemi I, Meistrich ML. Failure of spermatogenesis to recover despite the presence of A spermatogonia in the irradiated LBNF1 rat. Biol Reprod 1996; 54: 1200–8.
50. Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985; 65: 832–6.
51. Thomson AB, Anderson RA, Irvine DS, et al. Investigation of suppression of the hypothalamic-pituitary-gonadal axis to restore spermatogenesis in azoospermic men treated for childhood cancer. Hum Reprod 2002; 17: 1715–23.
52. Sharpe RM, Walker M, Millar MR, et al. Effect of neonatal gonadotropin-releasing hormone antagonist administration on sertoli cell number and testicular development in the marmoset: comparison with the rat. Biol Reprod 2000; 62: 1685–93.
53. Kelnar CJ, McKinnell C, Walker M, et al. Testicular changes during infantile “quiescence” in the marmoset and their gonadotrophin dependence: a model for investigating susceptibility of the prepubertal human testis to cancer therapy? Hum Reprod 2002; 17: 1367–78.
54Gillick v West Norfolk and Wisbech Area Authority. All England Law Reports 1985; 402.
55. Human Fertilisation and Embryology Act 1990. Chapter 37. London: HMSO.
56. Grundy R, Larcher V, Gosden RG, et al. Fertility preservation for children treated for cancer (2): ethics of consent for gamete storage and experimentation. Arch Dis Child 2001; 84: 360–2.
57. Wallace WH, Walker DA. Conference consensus statement: ethical and research dilemmas for fertility preservation in children treated for cancer. Hum Fertil (Camb) 2001; 4: 69–76.